Vertex Pharmaceuticals, Inc. XNAS: VRTX

Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Name: Vertex Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Vertex Pharmaceuticals, Inc.
Rating: 1.967527875
Author: Trendlyne DVM scores

Momentum Trap

about

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

463.86 -5.82 (-1.24%)

27.96% Gain from 52W Low

1.7M

XNAS Volume

XNAS 09 Jan, 2026 4:30 PM (EST)

Board Meeting

The board meeting for Vertex Pharma is scheduled for today, for the purpose of 44 Annual J.P. Morgan Healthcare Conference See details

Low Financial Strength

27.8 / 100

Mid Valuation

39.2 / 100

Technically Moderately Bullish

62.7 / 100

Momentum Trap These stocks have average financials but are currently seeing momentum. Investors should exercise caution in buying these stocks View Similar Embed DVM

500

1Yr Price target upside is 8%

25 analysts

Vertex Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

27.96% Gain from 52W Low

SWOT Analysis

Vertex Pharma Live Price Chart